Page last updated: 2024-11-13

lusutrombopag

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lusutrombopag: a thrombopoietin receptor agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID49843517
CHEMBL ID2107831
CHEBI ID136051
SCHEMBL ID3062084
SCHEMBL ID3062080

Synonyms (51)

Synonym
lusutrombopag
CHEBI:136051
rsc888711
s-888711
CHEMBL2107831
mulpleta
(2e)-3-(2,6-dichloro-4-((4-(3-((1s)-1-(hexyloxy)ethyl)- 2-methoxyphenyl)-1,3-thiazol-2-yl)carbamoyl)phenyl)-2-methylprop-2-enoic acid
2-propenoic acid, 3-(2,6-dichloro-4-(((4-(3-((1s)-1-(hexyloxy)ethyl)-2-methoxyphenyl)-2-thiazolyl)amino)carbonyl)phenyl)-2-methyl-, (2e)-
lusutrombopag [usan:inn]
s 888711
(2e)-3-(2,6-dichloro-4-((4-(3-((1s)-1-(hexyloxy)ethyl)-2-methoxyphenyl)-1,3-thiazol-2-yl)carbamoyl)phenyl)-2-methylprop-2-enoic acid
6ll5jfu42f ,
1110766-97-6
unii-6ll5jfu42f
mulpleta (tn)
D10476
lusutrombopag (jan/usan/inn)
S6988
lusutrombopag [orange book]
lusutrombopag [who-dd]
lusutrombopag [mi]
lusutrombopag [jan]
lusutrombopag [usan]
(2e)-3-{2,6-dichloro-4-[(4-{3-[(1s)-1-(hexyloxy)ethyl]-2-methoxyphenyl}-1,3-thiazol-2-yl)carbamoyl]phenyl}-2-methylprop-2-enoic acid
lusutrombopag [inn]
SCHEMBL3062084
SCHEMBL3062080
AC-30601
(s,e)-3-(2,6-dichloro-4-((4-(3-(1-(hexyloxy)ethyl)-2-methoxyphenyl)thiazol-2-yl)carbamoyl)phenyl)-2-methylacrylic acid
CS-6137
HY-19883
EX-A1290
AKOS027337127
2-propenoic acid, 3-[2,6-dichloro-4-[[[4-[3-[(1s)-1-(hexyloxy)ethyl]-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-, (2e)-
AS-52368
(e)-3-[2,6-dichloro-4-[[4-[3-[(1s)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid
s888711 ,
gtpl10032
lusutrombopags-888711
DB13125
mfcd28502075
NCGC00522464-01
Q27265116
(e)-3-[2,6-dichloro-4-[4-[3-[(s)-1-hexyloxyethyl]-2-methoxyphenyl]thiazol-2-ylcarbamoyl]phenyl]-2-methylacrylic acid
A927042
bdbm430660
DTXSID701027951
EN300-7383464
b02bx07
(2e)-3-(2,6-dichloro-4-((4-(3-((1s)-1-(hexyloxy)ethyl)-2-methoxyphenyl)-1,3-thiazol-2-yl)carbamoyl)phenyl)-2-methylprop-2-enoic acid
lusutrombopagum

Research Excerpts

Overview

Lusutrombopag reduces the need for platelet transfusions before planned invasive procedures. It is an agonist of the throm bopoietin receptor that activates platelet production. Lusutropa is being developed by Shionogi for chronic liver disease patients.

ExcerptReferenceRelevance
"Lusutrombopag is a thrombopoietin receptor agonist which reduces the need for platelet transfusions before planned invasive procedures. "( A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series.
Biolato, M; Grieco, A; Marrone, G; Miele, L; Vitale, F, 2022
)
2.49
"Lusutrombopag is an agonist of the thrombopoietin receptor that activates platelet production."( Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma.
Alkhouri, N; Bentley, R; Imawari, M; Izumi, N; Kano, T; Ochiai, T; Osaki, Y; Trevisani, F, 2020
)
2.72
"Lusutrombopag is an effective and safe drug for thrombocytopenia in cirrhotic patients, and can reduce the frequency of platelet transfusions."( Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
Enomoto, N; Higuchi, M; Itakura, J; Izumi, N; Komiyama, Y; Kubota, Y; Kurosaki, M; Nakanishi, H; Okada, M; Shimizu, T; Takada, H; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Watakabe, K; Yasui, Y, 2019
)
2.26
"Lusutrombopag is a novel, orally active thrombopoietin receptor agonist. "( Effects of Food and Calcium Carbonate on the Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist.
Fukuhara, T; Kano, T; Katsube, T; Wajima, T, 2019
)
2.19
"Lusutrombopag (Mulpleta®) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery. "( Lusutrombopag: First Global Approval.
Kim, ES, 2016
)
3.32

Effects

ExcerptReferenceRelevance
"Lusutrombopag has a little stronger effect in patients with mild thrombocytopenia than those with severe thrombocytopenia and showed a more substantial effect in patients with impaired renal function and small spleen."( Lusutrombopag has slightly stronger effects on patients with mild thrombocytopenia compared with those with severe thrombocytopenia: A multicenter propensity score matching study.
Arai, T; Arase, Y; Atsukawa, M; Furuichi, Y; Hidaka, H; Itoi, T; Kako, M; Takeuchi, H; Uojima, H, 2022
)
3.61

Toxicity

ExcerptReferenceRelevance
" However, lusutrombopag is effective and safe for CLD patients with a platelet count of < 50,000/µL."( Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study.
Isoda, N; Koyashiki, Y; Kurata, H; Maeda, H; Miura, K; Morimoto, N; Nomoto, H; Numao, N; Sasaki, T; Takaoka, Y; Watanabe, S; Yamamoto, H, 2020
)
2.4

Pharmacokinetics

This report describes 3 studies aimed at assessing the effects of food and calcium carbonate on the pharmacokinetic parameters of lusutrombopag in healthy subjects. The aim of this study was to develop a population pharmacokinetics (PK)/pharmacodynamic (PD) model.

ExcerptReferenceRelevance
"The aim of this study was to develop a population pharmacokinetic (PK)/pharmacodynamic (PD) model for describing plasma lusutrombopag concentrations and platelet response following oral lusutrombopag dosing and for evaluating covariates in the PK/PD profiles."( Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects.
Ishibashi, T; Kano, T; Katsube, T; Wajima, T, 2016
)
0.89
" This report describes 3 studies aimed at assessing the effects of food and calcium carbonate on the pharmacokinetic parameters of lusutrombopag in healthy subjects."( Effects of Food and Calcium Carbonate on the Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist.
Fukuhara, T; Kano, T; Katsube, T; Wajima, T, 2019
)
0.96
" Pharmacokinetic parameters were estimated from plasma lusutrombopag concentrations."( Effects of Food and Calcium Carbonate on the Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist.
Fukuhara, T; Kano, T; Katsube, T; Wajima, T, 2019
)
1

Dosage Studied

ExcerptRelevanceReference
"The aim of this study was to develop a population pharmacokinetic (PK)/pharmacodynamic (PD) model for describing plasma lusutrombopag concentrations and platelet response following oral lusutrombopag dosing and for evaluating covariates in the PK/PD profiles."( Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects.
Ishibashi, T; Kano, T; Katsube, T; Wajima, T, 2016
)
0.89
" Chemical structures, available dosage forms, recommended dosing, pharmacokinetics, results of toxicity studies in animals, most frequent adverse effects, significant outcomes of the corresponding clinical trials, and their use in specific patient populations are thoroughly described."( New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations.
Al-Horani, RA; Clemons Bankston, P, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cinnamic acidsAny alpha,beta-unsaturated monocarboxylic acid based on the cinnamic acid skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency14.12540.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)3.78000.00022.45859.9600AID1804171
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thrombopoietin receptorHomo sapiens (human)ED500.00110.00110.00110.0011AID1340985
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
neutrophil homeostasisThrombopoietin receptorHomo sapiens (human)
monocyte homeostasisThrombopoietin receptorHomo sapiens (human)
positive regulation of lymphocyte proliferationThrombopoietin receptorHomo sapiens (human)
cellular response to hypoxiaThrombopoietin receptorHomo sapiens (human)
positive regulation of platelet formationThrombopoietin receptorHomo sapiens (human)
eosinophil homeostasisThrombopoietin receptorHomo sapiens (human)
basophil homeostasisThrombopoietin receptorHomo sapiens (human)
thrombopoietin-mediated signaling pathwayThrombopoietin receptorHomo sapiens (human)
immunoglobulin mediated immune responseThrombopoietin receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein bindingThrombopoietin receptorHomo sapiens (human)
thrombopoietin receptor activityThrombopoietin receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
Golgi apparatusThrombopoietin receptorHomo sapiens (human)
plasma membraneThrombopoietin receptorHomo sapiens (human)
cell surfaceThrombopoietin receptorHomo sapiens (human)
nuclear membraneThrombopoietin receptorHomo sapiens (human)
neuronal cell bodyThrombopoietin receptorHomo sapiens (human)
external side of plasma membraneThrombopoietin receptorHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1804171DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\2020Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's14 (45.16)24.3611
2020's17 (54.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.46 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index60.21 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (17.65%)5.53%
Reviews6 (17.65%)6.00%
Case Studies6 (17.65%)4.05%
Observational0 (0.00%)0.25%
Other16 (47.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]